Search Results

There are 8049 results for: content related to: Association of anti- IL -12/23 biologic agents ustekinumab and briakinumab with major adverse cardiovascular events

  1. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease

    Intervention Review

    The Cochrane Library

    John K MacDonald, Tran M Nguyen, Reena Khanna and Antje Timmer

    Published Online : 25 NOV 2016, DOI: 10.1002/14651858.CD007572.pub3

  2. Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points

    Journal of the European Academy of Dermatology and Venereology

    Volume 28, Issue 12, December 2014, Pages: 1633–1653, L. Puig, A. López, E. Vilarrasa and I. García

    Version of Record online : 19 AUG 2013, DOI: 10.1111/jdv.12238

  3. You have free access to this content
    Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

    Journal of the European Academy of Dermatology and Venereology

    Volume 27, Issue 12, December 2013, Pages: 1535–1545, A.B. Kimball, K.A. Papp, Y. Wasfi, D. Chan, R. Bissonnette, H. Sofen, N. Yeilding, S. Li, P. Szapary, K.B. Gordon and on behalf of the PHOENIX 1 investigators

    Version of Record online : 20 DEC 2012, DOI: 10.1111/jdv.12046

  4. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases

    International Journal of Dermatology

    Volume 54, Issue 10, October 2015, Pages: 1194–1198, Naomi Takahashi, Shinji Noda, Takashi Taniguchi and Makoto Adachi

    Version of Record online : 27 MAY 2015, DOI: 10.1111/ijd.12859

  5. Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis

    Clinical and Experimental Dermatology

    Volume 39, Issue 6, August 2014, Pages: 696–707, Y. Meng, L. Dongmei, P. Yanbin, F. Jinju, T. Meile, L. Binzhu, H. Xiao, T. Ping and L. Jianmin

    Version of Record online : 14 JUL 2014, DOI: 10.1111/ced.12390

  6. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

    British Journal of Dermatology

    Volume 166, Issue 4, April 2012, Pages: 861–872, A.B. Kimball, K.B. Gordon, S. Fakharzadeh, N. Yeilding, P.O. Szapary, B. Schenkel, C. Guzzo, S. Li and K.A. Papp

    Version of Record online : 27 MAR 2012, DOI: 10.1111/j.1365-2133.2012.10901.x

  7. Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters

    The Journal of Dermatology

    Volume 37, Issue 5, May 2010, Pages: 413–425, Manjula REDDY, Gisela TORRES, Thomas McCORMICK, Colleen MARANO, Kevin COOPER, Newman YEILDING, Yuhua WANG, Charles PENDLEY, Uma PRABHAKAR, Jackson WONG, Cuc DAVIS, Stephen XU and Carrie BRODMERKEL

    Version of Record online : 9 APR 2010, DOI: 10.1111/j.1346-8138.2010.00802.x

  8. Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis – nationwide results from the DERMBIO registry

    Journal of the European Academy of Dermatology and Venereology

    A. Egeberg, L. Iversen, R. Gniadecki, L. Hvid, T.N. Dam, L.E. Bryld and L. Skov

    Version of Record online : 29 MAR 2017, DOI: 10.1111/jdv.14200

  9. Population-Based Exposure-Efficacy Modeling of Ustekinumab in Patients With Moderate to Severe Plaque Psoriasis

    The Journal of Clinical Pharmacology

    Volume 50, Issue 3, March 2010, Pages: 257–267, Dr Honghui Zhou, Dr Chuanpu Hu, Dr Yaowei Zhu, Dr Ming Lu, Dr Sam Liao, Dr Newman Yeilding and Dr Hugh M. Davis

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270009343695

  10. You have free access to this content
    Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial

    The Journal of Dermatology

    Volume 39, Issue 3, March 2012, Pages: 242–252, Atsuyuki IGARASHI, Takeshi KATO, Mai KATO, Michael SONG, Hidemi NAKAGAWA and THE JAPANESE USTEKINUMAB STUDY GROUP

    Version of Record online : 29 SEP 2011, DOI: 10.1111/j.1346-8138.2011.01347.x

  11. Efficacy and Safety of Ustekinumab in Japanese Patients with Severe Atopic Dermatitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Study

    British Journal of Dermatology

    Accepted manuscript online: 24 MAR 2017, H. Saeki, K. Kabashima, Y. Tokura, Y. Murata, A. Shiraishi, R. Tamamura, B. Randazzo and K. Imanaka

    DOI: 10.1111/bjd.15493

  12. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-il-12/23p40 monoclonal antibody, during pregnancy and lactation

    Birth Defects Research Part B: Developmental and Reproductive Toxicology

    Volume 89, Issue 5, October 2010, Pages: 351–363, Pauline L. Martin, Clifford Sachs, Noritaka Imai, Hideshi Tsusaki, Satoru Oneda, Qun Jiao and George Treacy

    Version of Record online : 10 JUN 2010, DOI: 10.1002/bdrb.20250

  13. Ustekinumab: Lessons Learned from Targeting Interleukin-12/23p40 in Immune-Mediated Diseases

    Annals of the New York Academy of Sciences

    Volume 1182, Issue 1, December 2009, Pages: 97–110, Michael Elliott, Jacqueline Benson, Marion Blank, Carrie Brodmerkel, Daniel Baker, Kristin Ruley Sharples and Philippe Szapary

    Version of Record online : 10 DEC 2009, DOI: 10.1111/j.1749-6632.2009.05070.x

  14. You have free access to this content
    The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection

    British Journal of Dermatology

    Volume 167, Issue 5, November 2012, Pages: 1145–1152, T.-F. Tsai, V. Ho, M. Song, P. Szapary, T. Kato, Y. Wasfi, S. Li, Y.K. Shen, C. Leonardi, on behalf of the PHOENIX 1, PHOENIX 2, ACCEPT, PEARL and Japanese Ustekinumab Study Groups

    Version of Record online : 29 OCT 2012, DOI: 10.1111/j.1365-2133.2012.11142.x

  15. Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis

    The Journal of Clinical Pharmacology

    Volume 49, Issue 2, February 2009, Pages: 162–175, Dr Yaowei Zhu, Dr Chuanpu Hu, Dr Ming Lu, Dr Sam Liao, Dr Joseph C. Marini, Dr Jennifer Yohrling, Dr Newman Yeilding, Dr Hugh M. Davis and Dr Honghui Zhou

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270008329556

  16. Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry

    British Journal of Dermatology

    J. Zweegers, J.M.M. Groenewoud, J.M.P.A. van den Reek, M.E. Otero, P.C.M. van de Kerkhof, R.J.B. Driessen, P.P.M. van Lümig, M.D. Njoo, P.M. Ossenkoppele, J.M. Mommers, M.I.A. Koetsier, W.P. Arnold, M.P.M. Andriessen, A.L.A. Kuijpers, M.A.M. Berends, W. Kievit and E.M.G.J. de Jong

    Version of Record online : 10 MAR 2017, DOI: 10.1111/bjd.15023

  17. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C

    British Journal of Dermatology

    Volume 169, Issue 6, December 2013, Pages: 1295–1303, H.-Y. Chiu, C.-H. Chen, M.-S. Wu, Y.-P. Cheng and T.-F. Tsai

    Version of Record online : 2 DEC 2013, DOI: 10.1111/bjd.12461

  18. Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials

    Journal of the European Academy of Dermatology and Venereology

    Volume 25, Issue 7, July 2011, Pages: 851–857, L. Guenther, C. Han, P. Szapary, B. Schenkel, Y. Poulin, M. Bourcier, J.P. Ortonne and H.L. Sofen

    Version of Record online : 27 APR 2011, DOI: 10.1111/j.1468-3083.2011.04082.x

  19. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris

    British Journal of Dermatology

    Volume 172, Issue 1, January 2015, Pages: 244–252, R. Gniadecki, B. Bang, L.E. Bryld, L. Iversen, S. Lasthein and L. Skov

    Version of Record online : 30 NOV 2014, DOI: 10.1111/bjd.13343

  20. The risk of deep fungal infections during biologic therapy for psoriasis

    Journal of the European Academy of Dermatology and Venereology

    Volume 28, Issue 10, October 2014, Pages: 1277–1285, N. Jourabchi, L. Adelzadeh and J.J. Wu

    Version of Record online : 10 JUN 2014, DOI: 10.1111/jdv.12508

    Corrected by:

    Erratum: Erratum

    Vol. 29, Issue 1, 193–194, Version of Record online: 22 DEC 2014